Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011

March 29, 2011 - PRLog -- GlobalData analysis finds that the global gastric cancer therapeutics market is attractive, and is primarily driven by the growth in the number of patients receiving gastric cancer therapy and the annual cost of therapy. The patient volume is primarily driven by an increase in patient volume in countries such as China, France, Spain and Italy. The patient volume was driven by growth in treatment usage patterns such as diseased population, treatment seeking population, diagnosis population and prescription population. The annual cost of gastric cancer therapy was driven by the launch of new therapies such as Taxotere (docetaxel), Xeloda (capecitabine) and Herceptin (trastuzumab).

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Gastric-Cancer-Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-Volume-1-2011&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

There is no standard care for gastric cancer. The treatment of gastric cancer is largely based on the treatment guidelines of different countries. Very few drugs are actually approved for gastric cancer, although many drugs are recommended for use
in treatment. Taxotere is approved as a first line therapy in gastric cancer. The introduction of new therapies for metastatic gastric cancer is expected to expand the market further.

In 2010, Japan was the leading market in the global gastric cancer therapeutics market with an estimated market share of approximately 24.7%. China was the second leading market with 17% market share. The US is the third largest gastric cancer market with a 15% market share. Japan and China lead the market due to a large patient base.

In 2010, Taxotere was the leading drug with approximate sales worth $170m and a market share of 30%. Herceptin, which was launched in the US and EU in 2010, is expected to gain market share in the forecast period 2010-2020.

GlobalData, the industry analysis specialist, has released its new report, “Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 – Volume I 2011”. The report is an essential source of information and analysis on the global gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global gastric cancer therapeutics market. It analyses the treatment usage patterns in the global gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global gastric cancer sector. It quantifies the unmet need in the global gastric cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Gast...

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com            
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.